scholarly journals In memory of Professor Valentin N. Guryev

2021 ◽  
Vol 28 (2) ◽  
pp. 88-88
Keyword(s):  
Medical Research ◽  
Medical Care ◽  
The State ◽  
Research Center ◽  
Scientific Development ◽  
State Prize ◽  
Medical Sciences ◽  
Concomitant Injuries ◽  
National Medical ◽  
Great Patriotic War

At the 99th year of his life, Valentin Nikolayevich Guryev, Honored Scientist, Laureate of the State Prize of the USSR, Doctor of Medical Sciences, Professor, Veteran of the Great Patriotic War, was gone. He made an enormous contribution to the organization and scientific development of medical care by a team of specialists at the prehospital stage, which made it possible to reduce mortality in patients with multiple and concomitant injuries by one third. The collective of the N.N. Priorov National Medical Research Center of Traumatology and Orthopedics grieves over the loss, the bright memory of a talented surgeon, scientist, organizer, cheerful and charming person will forever remain in the hearts of friends, colleagues and students.

scholarly journals Optimization of the Research and Advisory Department of the Oncological Center

2019 ◽  
pp. 35-39
Author(s):  
Igor Anatolevich Doroshev ◽  
Ivan Sokratovich Stilidi ◽  
Zhanna Aleksandrovna Zavolskaia ◽  
Denis Anatolevich Riabchikov ◽  
Vadim Maratovich Kulushev ◽  
...  
Keyword(s):  
Medical Research ◽  
Medical Care ◽  
Health Facilities ◽  
Research Center ◽  
Medical Institution ◽  
Ministry Of Health ◽  
National Medical ◽  
Quality Of Medical Care ◽  
Oncological Center

The article provides an example of a successful optimization of the work in a research and advisory department of N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of Russia. All stages of this process are described in detail – from creating a project office and identifying problems to implementing methods for solving them and evaluating results. This work resulted in improving of the quality of medical care provided to the population, which is the most important task of any medical institution. In addition, this optimization experience may be useful for the implementation of similar activities in other health facilities in Russia.

scholarly journals State of Specialized Outpatient Trauma and Orthopedic Care in the Russian Federation. Development Perspectives

2017 ◽  
pp. 5-10 ◽  
Author(s):  
N. A. Es’kin ◽  
T. M. Andreeva
Keyword(s):  
Medical Research ◽  
Musculoskeletal Disorders ◽  
Russian Federation ◽  
Outpatient Care ◽  
The State ◽  
Research Center ◽  
National Medical ◽  
Orthopedic Care ◽  
The Russian Federation ◽  
Injured Patients

N.N. Priorov National Medical Research Center of Traumatology and Orthopaedics, Moscow, Russia Injuries and musculoskeletal disorders are the most widely spread diseases. It is shown that the majority of injured patients and patients with orthopedic pathology require an outpatient care. The state of specialized outpatient care is analyzed and the ways of its perfection are proposed. 

IPILIMUMAB IN PATIENTS WITH DISSEMINATED MELANOMA: THE N.N. PETROV NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY EXPANDED ACCESS PROGRAM EXPERIENCE

2018 ◽  
Vol 64 (3) ◽  
pp. 388-393
Author(s):  
Yekaterina Anokhina ◽  
V. Rubinchik ◽  
Yekaterina Yaremenko ◽  
Gulfiya Teletaeva ◽  
Dilorom Latipova ◽  
...  
Keyword(s):  
Overall Survival ◽  
Adverse Events ◽  
Medical Research ◽  
Research Center ◽  
Expanded Access ◽  
Risk Of Death ◽  
National Medical ◽  
Expanded Access Program ◽  
Access Program

Ipilimumab (IPI) provides a ten-year overall survival in almost 20 % of selected patients participated in several phase II-III trials. However, the expanded access program (EAP) looks more like routine practice than like clinical trials& This is why the results of such application could be different. Here we present the long-term follow-up data of single center EAP. Ninety-six patients with disseminated melanoma progressing after at least one lines of drug therapy were included at the N.N. Petrov National Medical Research Center of Oncology. Sixty-seven (70 %) patients had stage IV M1c, 35 patients (36 %) had elevated LDH before initiating IPI therapy. All patients received IPI 3 mg / kg IV every 3 weeks for a maximum of 4 cycles. Totally, 320 cycles (mean - 3.3 per patient) were conducted. Grade 3-4 immuno-mediated adverse events (imAE) observed in 18 (19 %) patients. Three patients died of adverse events, possibly associated with ongoing therapy. The median time to progression was 3 (95 % CI, 2.4 to 3.5) mo., the median overall survival was 13 (95 % CI, 8.3 to17.6) mo. Previous immunotherapy with dendritic cell vaccines decreased the risk of death by 48 % (Log-rank p = 0.049). The wild type BRAF status increased three-year overall survival from 29 to 68 % (p = 0.042). Our data confirms long-term safety and efficacy of IPI in patients with pretreated disseminated melanoma in the close to real practice setting.

scholarly journals Pharmacokinetics of 13-cis-Retinoic acid in high-risk neuroblastoma patients

2020 ◽  
Vol 19 (4) ◽  
pp. 20-31
Author(s):  
E. A. Litvin ◽  
D. T. Utalieva ◽  
D. Yu. Kachanov ◽  
A. V. Pshonkin ◽  
M. Ya. Yadgarov ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
High Risk ◽  
Medical Research ◽  
High Performance ◽  
Plasma Concentrations ◽  
Neuroblastoma Cells ◽  
Research Center ◽  
Therapeutic Drug ◽  
Pediatric Hematology ◽  
National Medical

13-cis-Retinoic acid is a differentiation agent for neuroblastoma cells and is a part of post-consolidation therapy for high-risk patients. The effectiveness of this therapeutic approach is currently under study. 26 patients with high-risk neuroblastoma treated at Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology were included in the study of 13-cis-Retinoic acid pharmacokinetics by high-performance liquid chromatography assay with ultraviolet detector depending on the method of administration of drug (swallowed capsules or opened capsules before administration). This study is supported by the Independent Ethics Committee and approved by the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The current study showed that the therapeutic concentration of > 2 μM when taking 13-cis-Retinoic acid at a dose of 160 mg/m2/day was achieved in two groups, regardless of the method of drug administration. However, plasma concentrations of 13-cis-Retinoic acid at 4 hours after administration on the 14th day of therapy were higher in the group of patients who swallowed the capsules (4.1 ± 1.8 μM), compared to those who could not do it (1.9 ± 1.5 μM) (p = 0.022). The introduction into the clinical practice of therapeutic drug monitoring of 13-cis-retinoic acid in high-risk neuroblastoma patients with an assessment of peak concentration and dose adjustment of the following courses may be an important point in the attempt to optimize postconsolidation therapy and improve prognosis.

scholarly journals Cervical Cytology–Histology Correlation Based on the American Society of Cytopathology Guideline (2017) at the Russian National Medical Research Center for Obstetrics, Gynecology, and Perinatology

Diagnostics ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 210
Author(s):  
Aleksandra Asaturova ◽  
Darya Dobrovolskaya ◽  
Alina Magnaeva ◽  
Anna Tregubova ◽  
Guldana Bayramova ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Medical Research ◽  
Sampling Error ◽  
Pap Test ◽  
Research Center ◽  
National Medical ◽  
American Society ◽  
Screening Errors ◽  
Discrepancy Detection ◽  
Self Learning

Recent evidence suggests that a cytology–histology correlation (CHC) with discrepancy detection can both evaluate errors and improve the sensitivity and specificity of the cytologic method. We aimed to analyze the errors in cytologic–histologic discrepancies according to the CHC protocol guideline of the American Society of Cytopathology (2017). This retrospective study included 273 patients seen at the National Medical Research Center of Obstetrics, Gynecology and Perinatology (Moscow, Russia) between January 2019 and September 2021. The patients’ mean age was 34 ± 8.1 years. The cytology–histology agreement was noted in 158 cases (57.9%). Major discrepancies were found in 21 cases (7.6%), while minor discrepancies were noted in 93 cases (34.1%). The reason for 13 (4.8%) discrepancies was a colposcopy sampling error and, in 46 (16.8%) cases, the reason was a Papanicolaou (PAP) test sampling error. The discrepancy between primary and reviewed cytology was due interpretive errors in 13 (4.8%) cases and screening errors in 42 (15.4%) cases. We demonstrated that the ASC guidelines facilitate cervical CHC. A uniform application of these guidelines would standardize cervical CHCs internationally, provide a scope for the inter-laboratory comparison of data, and enhance self-learning and peer learning.

Sign in / Sign up

Export Citation Format

Share Document